Æ÷·³ > Áõ±ÇÆ÷·³ ¡å¡ã
  • Áõ±ÇÆ÷·³
  • ÀçÅ×Å©Æ÷·³
  • º¸ÇèÆ÷·³
> ºÐ·ù
¡å¡ã
  • ÀϹÝ
  • Áú¹®
  • ½ÃȲºÐ¼®
  • Á¾¸ñºÐ¼®
  • ¸Å¸Å³ëÇÏ¿ì
  • ¸Å¸ÅÀÏÁö
  • ÆÄ»ý
  • Æݵå
  • ä±Ç
  • ´º½º

abbvie ½ÇÀû¹ßÇ¥ 6
nagangdo 2021-10-29 21:26   Á¶È¸ : 1126
»çÀÚ¸¶ÀÚ.JPG (22 KB)

 

Ãâó ½ÃÅ· ¾ËÆÄ 

 

°¡ÀÌ´ø½º Àλó

¹è´ç±Ý ÀÎ»ó  ¹ßÇ¥ 

 

¶á±Ý¾øÀÌ ¿Ö ¾Öºêºñ °¡Á®¿Ô³Ä°í ¹°¾îº¸½Å´Ù¸é Á¦°¡  Æò´Ü 111.1 ¿¡  ¹°·ÁÀֱ⠶§¹®ÀÌÁÒ 

³î¶ø°Ôµµ »çÀÚ¸¶ÀÚ ........ÇÒ¸»À» ÀÒÀº ..

20211029211800_biquspdy.jpg

 

 

 

  • AbbVie (NYSE:ABBV): Q3 Non-GAAP EPS of $3.33 beats by $0.11; GAAP EPS of $1.78 misses by $0.22.
  • Revenue of $14.34B (+11.2% Y/Y) beats by $40M.
  • Raises 2021 GAAP Diluted EPS Guidance Range from $6.04 to $6.14 to $6.29 to $6.33; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.52 to $12.62 to $12.63 to $12.67 vs. $12.57 consensus.
  • Announces 2022 Dividend Increase of 8.5 Percent, Beginning with Dividend Payable in February 2022.

 

 

0 ÃßõÇϱ⠴ٸ¥ÀÇ°ß 0 |
¸ñ·Ïº¸±â ÄÚ¸àÆ®ÀÛ¼º ÄÚ¸àÆ®6
´ë´ë´ë´ë ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
¶ò¶Ë¶¯ ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
[* ºñȸ¿ø *] ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
nagangdo ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
[* ºñȸ¿ø *] ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç
nagangdo ´Ù¸¥ÀÇ°ß 0 Ãßõ 0
| µ¡±Û Á¡¾ÆÀÌÄÜ
  1. ´ñ±ÛÁÖ¼Òº¹»ç

¿å¼³, »óó ÁÙ ¼ö ÀÖ´Â ¾ÇÇÃÀº »ï°¡ÁÖ¼¼¿ä.